biopolymers-and-bioplastics-2016_scientifictracks-abstracts

6 / 30

Notes:
Page 23
Biopolymers and Bioplastics 2016
September 12-14, 2016
Volume 7, Issue 5(Suppl) J Bioremed Biodeg 2016
ISSN: 2155-6199 JBRBD, an open access journal
conferenceseries .com
September 12-14, 2016 San Antonio, USA
3rd International Conference and Exhibition onBiopolymers & Bioplastics
Bo Chen, J Bioremed Biodeg 2016, 7:5(Suppl)
The development of nonabsorbed potassium binding polymer microparticles (patiromer) for the treatment
of hyperkalemia
Bo Chen
Relypsa Inc., USA
Hyperkalemia is a potentially life-threatening condition, and patients who have chronic kidney disease, who are diabetic,
or who are taking renin-angiotensin-aldosterone system inhibitors are at increased risk. Therapeutic options for
hyperkalemia tend to have limited effectiveness and can be associated with serious side effects. There are no new therapeutics
for more than 50 years. Patiromer (USAN, trade name Veltassa) is a novel, spherical, nonabsorbed polymer designed to
bind and remove potassium, primarily in the colon, thereby decreasing serum potassium in patients with hyperkalemia. The
development process and the results of preclinical studies and early phase clinical study are reported here. Overall, patiromer is
a high-capacity potassium binder and the chemical and physical characteristics of patiromer can lead to good clinical efficacy,
tolerability and patient acceptance. It has been approved in 2015 by FDA used for the treatment of hyperkalemia.
Biography
Bo Chen is a Principal Scientist in Relypsa focusing on microparticles as toxin binders for various diseases. After his PhD in 2006 from New York University School
of Engineering, and Post-doctoral studies from University of California San Francisco in 2009, he started his Sanofi-Genzyme career in Biomaterials and Drug
Delivery Division. He left as a Senior Scientist in 2014 and joined biotech company CPGJ (Shanghai) as an Associate Director, later in GrayBug Inc. He has broad
experience in Antibody Drug Conjugate (ADC) and Drug Delivery. He has published more than 20 papers/patents. He has been serving as a Guest Editor of Current
Cancer Drug Targets since 2014.